Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05964192
Other study ID # 2023-A00288-37
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date June 30, 2029

Study information

Verified date July 2023
Source Centre Hospitalier Rouffach
Contact MIHAELA TOMSA
Phone +33 389787018
Email m.tomsa@ch-rouffach.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to determine the predictive value of the neuroendocrine tests TRH-∆∆TSH (thyreoliberin - thyreostimulin) and DST (dexamethasone suppression test) in the subsequent response to rTMS-TBS (repetitive transcranial magnetic stimulation-theta burst stimulation) treatment, defined as at least a 50% decrease in depression score after 20 sessions of rTMS-TBS.


Description:

Conduct of research : This is a monocentric, non-randomized, open-label pilot study involving 50 male and female patients aged 18 to 65, hospitalized for major depression and presenting with an indication for treatment with repeated theta-burst transcranial magnetic stimulation (rTMS-TBS), i.e. a situation of therapeutic failure following 2 well-conducted antidepressant treatments. At the end of the 20 rTMS-TBS sessions (one session per day, except weekends), the clinical response will be assessed by an investigator "blind" to the endocrine results. This response will be analyzed according to the status of neuroendocrine tests at inclusion (TRH-∆∆TSH and DST) and at the end of the study (for those who had one or more abnormal tests at inclusion and in whom the same tests were repeated at the end of the rTMS-TBS sessions). During the inclusion visit, the patient and investigator sign the consent form, after double-checking the inclusion and non-inclusion criteria. Immediately after the tenth rTMS session, an assessment of depression using the HAMD (17-item Hamilton Depression Scale) scale will be carried out by an independent psychiatrist, blind to the results of the neuroendocrine tests. This psychiatrist, who has already administered the HAMD at V0, will repeat the assessments at V1 and V2. Immediately after the twentieth rTMS session, an assessment of depression using the HAMD scale will be carried out by an independent psychiatrist. This assessment will determine responder/non-responder status to rTMS-TBS.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 30, 2029
Est. primary completion date September 1, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patient with a characterized depressive episode defined according to DSM-5 (diagnostic and statistical manual of mental disorders) criteria; 2. Patient between the ages of 18 and 65 years; 3. Inpatient with an inadequate response to two prior well-conducted antidepressant treatments (Hamilton 17-item scale [HAMD-17] score at inclusion= 18) ; 4. Patient with written informed consent to participate in the study; 5. Patient enrolled in or receiving social security benefits. Exclusion Criteria: 1. Patient with endocrinopathy ; 2. Patient with a contraindication to neuroendocrine testing (hypersensitivity to the active substance or to one of the excipients); 3. Patient with a contraindication to rTMS: - cochlear implant, - cardiac pacemaker, - metal clips, stents or other electronic implants within one meter of the stimulation coil, - intracranial hypertension, - poorly balanced comitiality, - in the case of well-balanced comitiality, a neurological consultation with electroencephalogram (EEG) is planned before including the patient; 4. Patient previously treated with monoamine oxidase inhibitor (MAOI) antidepressant or lithium salts (within 6 months prior to inclusion); 5. Pregnant or lactating patient; 6. Patient under court protection or deprived of liberty; 7. Patient under guardianship/guardianship.

Study Design


Intervention

Procedure:
Repetitive transcranial magnetic stimulation (rTMS)
The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).

Locations

Country Name City State
France Centre Hospitalier Rouffach Rouffach Alsace

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Rouffach

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary 17-item Hamilton Depression Scale (HAMD) Clinical response will be defined by at least a 50% decrease in depression score at the end of the 20 rTMS-TBS sessions - measured by the 17-item Hamilton Depression Scale (HAMD) - compared to inclusion (Carrozzino et al, 2020). The predictive value of the TRH-??TSH on the one hand, and the DST on the other, will be assessed using an ROC curve and its AUC (Area Under the Curve) calculation. Change from inclusion result at 6 weeks (after 20 rTMS-TBS sessions)
Secondary Hamilton Depression Scale (HAMD) Functional remission will be defined by a HAMD score = 8 at the end of 20 sessions of rTMS-TBS Through study completion, an average of 6 weeks
Secondary Evolution of neuroendocrine parameters Pre- and post-treatment difference in neuroendocrine test values Through study completion, an average of 6 weeks
Secondary Evolution of neuroendocrine parameters Proportion of patients having normalized their tests at the end of the 20 sessions of rTMs. Through study completion, an average of 6 weeks
Secondary Relationship of the therapeutic response with the evolution of neuroendocrine parameters Proportion of responders/functional remission patients according to the normalization or not of neuroendocrine tests after rTMS-TBS treatment. Through study completion, an average of 6 weeks
Secondary Predictive factors Predictors of response to rTMS treatment (e.g., demographics) Through study completion, an average of 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT03062150 - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression N/A
Completed NCT04352101 - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits Phase 4
Completed NCT02855918 - Blood Biomarkers in Suicidal Behaviour N/A
Recruiting NCT03039387 - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients N/A
Recruiting NCT02213016 - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Phase 4
Completed NCT01683539 - Understanding How Cognitive Remediation Works N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Recruiting NCT02237937 - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Phase 4
Completed NCT01201148 - Open Pilot Trial of TES for Depression Phase 2
Completed NCT00953108 - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients Phase 3
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Terminated NCT00695552 - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients N/A
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00806143 - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression Phase 4
Completed NCT00466323 - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness. N/A
Completed NCT00532480 - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine Phase 4
Completed NCT00482482 - Yoga in Unipolar and Bipolar Disorders N/A
Completed NCT00616759 - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Completed NCT00149110 - Chronos: the Use of Chronobiological Treatment in Depression N/A